NL-OMON36734已完成2 期
Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatment - Oral alitretinoin in PPP
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Male patients, or female patients if post-menopausal as defined in protocol section 7.4.1., or hysterectomized, or bilaterally ovarectomized, or if pre-menopausal and willing to use at least 1 but preferably 2 methods of contraception under supervision of the investigator or a gynecologist
- •2. Aged 18 to 75 years
- •3. Patients with PPP for at least 6 months, with or without psoriasis lesions on other areas of the skin
- •4. A PPPASI score of at least 8 with involvement of at least 10% of the palms and/or the soles
- •5. Refractory to standard topical therapy
- •6. Written informed consent provided
排除标准
- •1. Patients unable to comply with the requirements of the study
- •2. Female patients who are pregnant or who plan to become pregnant or who are breast feeding
- •3. Female patients of childbearing potential who cannot use or will not commit to using at least one but preferably two effective forms of contraception simultaneously under supervision of the investigator or a gynecologist
- •4. Patients whose disease is adequately controlled by standard non-medicated therapy (skin moisturizing and protection) and standard topical corticosteroid therapy, but whose disease has relapsed following discontinuation of these treatments
- •5. Patients with known hypersensitivity to other retinoids or vitamin A derivatives, or to any study medication component, especially soybean oil and partly hydrogenated soybean oil
- •6. Patients treated with any of the following treatments 4 weeks before the start of study treatment:
- •a. systemic drugs: corticosteroids, immunosuppressants, methotrexate
- •b. phototherapy: ultraviolet B light therapy [UVB], Psoralen with ultraviolet A combination therapy [PUVA], Grenz rays, X-rays
- •7. Patients treated with biologic treatments within 12 weeks prior to start of study treatment.
- •8. Patients treated with any systemic or topical retinoids within 1 year or 1 month, respectively, before start of study treatment, and patients who received systemic retinoids for treatment for PPP at any time
- •9. Patients with severe generalized pustular psoriasis
- •10. Patient has a skin condition of palms and/or soles which is assessed as unrelated to PPP by the investigator
- •11. Patients with any serious medical condition which, in the opinion of the investigator, may interfere with the safety of the patient
- •12. Patients with hepatic insufficiency, severe renal failure, uncontrolled hypercholesterinemia, uncontrolled as characterized by:
- •a. AST/ ALT > 2,5 x ULN
- •b. Creatinine clearance <60ml/min (calculated, Cockcroft-Gault)
- •c. Fasting triglyceridemia > 1.5 x ULN
- •d. Fasting cholesterol > 1.5 x ULN
- •e. Fasting LDL cholesterol > 1.5x ULN
- •13. Patients with hypothyroidism as indicated by TSH/T4 test <0.9 x LLN or hypervitaminosis A
- •14. Patients with cardiovascular risk factors that would exclude a starting dose of 30 mg of alitretinoin
- •15. Patients receiving drugs with a potential for drug-drug interaction, such as systemic tetracyclines, ketoconazole, or St. John*s Wort within 1 week, or receiving systemic itraconazole within 2 weeks, before start of study treatment
- •16. Patients included in the study of an investigational drug within 2 months before start of study treatment (3 months for biologics)
- •17. Patients with a score of 20 or more on CES-D, or with active major psychiatric disorder (e.g. Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar Disorder (I or II), or schizophrenia)
研究者
相似试验
进行中（未招募）
不适用
Efficacy of alitretinoin treatment in patients with pustular form of PsoriasisPalmo-Plantar PustulosisMedDRA version: 14.1Level: LLTClassification code 10050185Term: Palmoplantar pustulosisSystem Organ Class: 100000004858EUCTR2010-022843-39-NLGlaxoSmithKline R&D Ltd30
进行中（未招募）
不适用
Efficacy of alitretinoin treatment in patients with pustular form of PsoriasisEUCTR2010-022843-39-DEGlaxoSmithKline R&D Ltd30
进行中（未招募）
1 期
Efficacy of altiretinoin treatment in patients with pustular form of PsoriasisPalmo-Plantar PustulosisMedDRA version: 20.0 Level: LLT Classification code 10050185 Term: Palmoplantar pustulosis System Organ Class: 100000004858EUCTR2010-022843-39-GBGlaxoSmithKline R&D Ltd33
进行中（未招募）
不适用
Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand DermatitisSevere Chronic Hand Dermatitis (CHaD) Refractory to Topical TherapyEUCTR2005-004776-20-DEBasilea Pharmaceutica Ltd250
进行中（未招募）
不适用
Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous LupusErythematosus: A Multicentre, Open-Label, Prospective Pilot Study?dult subjects of any ethnicity and either gender with Subacute Cutaneous Lupus Erythematosus (SCLE), Discoid Lupus Erythematosus (DLE), Lupus erythematosus tumidus (LET) or Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions and without major organ involvement to investigate the efficacy of alitretinoin (30 mg per day) in the treatment of Cutaneous Lupus Erythematosus lesions.MedDRA version: 16.0Level: PTClassification code 10056509Term: Cutaneous lupus erythematosusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-024131-16-DEniversitätsklinikum Münster33